Company
Every investor coverage indicates participated in a round MacDougall Advisors raised.
Companies MacDougall Advisors acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming MacDougall Advisors. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Eye-drug developer Azura Ophthalmics, working from Melbourne and Tel Aviv, has assembled a seven-member scientific advisory board of ophthalmology specialists to guide clinical development of its lead candidate AZR-MD-001.
Azura Ophthalmics won a CUREator grant to fund a two-stage study of its AZR-MD-001 candidate for contact lens discomfort, extending pilot research conducted with UNSW; the incubator program is run by Brandon BioCatalyst.